Organogenesis Holdings (ORGO) Liabilities and Shareholders Equity (2016 - 2025)
Organogenesis Holdings (ORGO) has 10 years of Liabilities and Shareholders Equity data on record, last reported at $598.7 million in Q4 2025.
- For Q4 2025, Liabilities and Shareholders Equity rose 20.25% year-over-year to $598.7 million; the TTM value through Dec 2025 reached $2.0 billion, up 10.36%, while the annual FY2025 figure was $598.7 million, 20.25% up from the prior year.
- Liabilities and Shareholders Equity reached $598.7 million in Q4 2025 per ORGO's latest filing, up from $509.8 million in the prior quarter.
- Across five years, Liabilities and Shareholders Equity topped out at $598.7 million in Q4 2025 and bottomed at $319.2 million in Q1 2021.
- Average Liabilities and Shareholders Equity over 5 years is $449.5 million, with a median of $453.3 million recorded in 2022.
- Peak YoY movement for Liabilities and Shareholders Equity: skyrocketed 64.24% in 2021, then decreased 3.53% in 2024.
- A 5-year view of Liabilities and Shareholders Equity shows it stood at $443.3 million in 2021, then increased by 1.38% to $449.4 million in 2022, then increased by 2.37% to $460.0 million in 2023, then grew by 8.23% to $497.9 million in 2024, then increased by 20.25% to $598.7 million in 2025.
- Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $598.7 million in Q4 2025, $509.8 million in Q3 2025, and $461.1 million in Q2 2025.